Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

At this time, I would like to welcome everyone to the Q3 2024 Emergent BioSolutions Inc. earnings conference call. All lines ...

November 6, 2024Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is $1.37, expectations were $0.14.

Emergent Biosolutions (EBS) stock rose 14% post-market after the company raised the lower end of its revenue guidance range ...

On Thursday, Emergent BioSolutions Inc. (NYSE:EBS) stock is trading higher on mixed third-quarter earnings and a new mpox ...

Emergent Biosolutions ( (EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its ...

Emergent BioSolutions (EBS) is up 23.7%, or $2.18 to $11.38. Published first on TheFly – the ultimate source for real-time, ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.

On a per-share basis, the Gaithersburg, Maryland-based company said it had profit of $2.06. Earnings, adjusted for non-recurring gains, were $1.37 per share. The biopharmaceutical company posted ...

Emergent BioSolutions appointed Dr. Simon Lowry as chief medical officer and head of research and development. CureVac named ...

Thursday after the company reported strong third-quarter results, lifting retail sentiment. Earnings per share for Q3 came in ...